Cadrenal Therapeutics (NASDAQ: CVKD) names interim CFO and realigns board classes
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Cadrenal Therapeutics, Inc. appointed John P. Sharp as Interim Chief Financial Officer, replacing Quang X. Pham in that role while he remains Chairman and CEO. Sharp will serve through consulting firm Lohman & Associates under a Master Services Agreement and a new Statement of Work. Lohman will bill $455/hour for up to 24 hours per week of Sharp’s services. Separately, director Steven Zelenkofske resigned effective June 30, 2026, and the Board realigned its classified structure by moving director Glynn Wilson to the Class III seat, reappointing him to the Audit and Nominating and Corporate Governance Committees and adding him to the Compensation Committee. Non-employee directors receive an annual cash fee of $35,000 for Board service in 2026, plus equity awards.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Interim CFO hourly rate: $455/hour
Weekly hours cap: 24 hours per week
Director annual cash fee: $35,000
+3 more
6 metrics
Interim CFO hourly rate
$455/hour
Flat rate for John Sharp’s services under SOW5
Weekly hours cap
24 hours per week
Maximum billed Interim CFO hours before extra approval
Director annual cash fee
$35,000
Non-employee director Board fee for fiscal year 2026
Effective date interim CFO appointment
June 25, 2026
John Sharp begins serving as Interim CFO
Director resignation effective date
June 30, 2026
Effective date of Steven Zelenkofske’s resignation
Board class term end
2028 annual meeting
End of term for Dr. Wilson as Class III director
Key Terms
Interim Chief Financial Officer, Master Services Agreement, Statement of Work, Class III member of the Board, +2 more
6 terms
Interim Chief Financial Officer financial
"appointed John P. Sharp as Interim Chief Financial Officer of the Company"
An interim chief financial officer is a temporary leader responsible for managing a company's financial activities, such as budgeting, financial planning, and reporting, during a transitional period. Think of it as filling in for a key manager until a permanent replacement is found. For investors, this role is important because it ensures financial stability and clear guidance during times of change or uncertainty.
Master Services Agreement financial
"subject to the provisions of a Master Services Agreement, dated August 21, 2024"
A master services agreement is a standing contract that sets the main terms, responsibilities, pricing framework and processes for future work between two parties, allowing individual projects or orders to be added later without renegotiating core terms. For investors, it signals predictability and reduced legal friction around revenue streams and costs—like a subscription plan for services that makes future income and obligations easier to forecast and value.
Statement of Work financial
"Scope of Work Number Five (“SOW5”), which sets forth the services to be provided"
A statement of work (SOW) is a written agreement that spells out what work will be done, who will do it, when it will be finished, how success is measured, and how payment will be handled. Think of it as a detailed recipe and timeline for a project that both sides sign off on. For investors, an SOW matters because it creates predictable revenue and obligations, clarifies milestones and risks, and helps assess whether a company can deliver on contracts and meet financial forecasts.
Class III member of the Board financial
"On June 28, 2026, Steven Zelenkofske, a Class III member of the Board"
Audit Committee financial
"the Board reappointed Dr. Wilson to the Audit Committee"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
Nominating and Corporate Governance Committee financial
"and the Nominating and Corporate Governance Committee"
A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.
FAQ
What leadership change did Cadrenal Therapeutics (CVKD) disclose in this 8-K?
Cadrenal Therapeutics appointed John P. Sharp as Interim Chief Financial Officer, replacing Quang X. Pham in that role. Sharp serves through consulting firm Lohman & Associates under an existing Master Services Agreement and a new Statement of Work effective June 25, 2026.
How is Cadrenal Therapeutics (CVKD) compensating its interim CFO?
Cadrenal will pay Lohman & Associates $455 per hour for up to 24 hours per week of John Sharp’s services as Interim CFO. Any additional hours, out-of-scope work, travel, or rate changes require written approval from both Cadrenal and Lohman & Associates.
Which Cadrenal Therapeutics (CVKD) director resigned and when is it effective?
Director Steven Zelenkofske, a Class III board member, notified Cadrenal of his resignation effective June 30, 2026. The company states his resignation was not due to any disagreement regarding operations, policies, or practices, indicating an orderly, non-dispute-related board change.
How did Cadrenal Therapeutics (CVKD) realign its classified board structure?
To keep its three board classes as equal in size as practicable, Cadrenal moved Dr. Glynn Wilson from Class I to Class III on June 29, 2026. He will serve until the 2028 annual meeting or until a successor is elected and qualified, or earlier departure.
What committee roles does Dr. Glynn Wilson hold at Cadrenal Therapeutics (CVKD)?
Following the board realignment, Dr. Glynn Wilson was reappointed to the Audit Committee and the Nominating and Corporate Governance Committee and newly appointed to the Compensation Committee. These assignments position him across Cadrenal’s key oversight, governance, and executive compensation functions.
What compensation do Cadrenal Therapeutics (CVKD) non-employee directors receive in 2026?
For the fiscal year ending December 31, 2026, Cadrenal’s non-employee directors receive an annual fee of $35,000 for Board service. They are also eligible for equity awards from time to time, aligning a portion of their compensation with shareholder interests.